Latest Insights,YKYY, a antihypertensive peptide

The quest for natural and effective ways to manage blood pressure has led to significant research into angiotensin-converting enzyme (ACE) inhibitory peptides. These peptides are short chains of amino acids that can block the action of ACE, an enzyme crucial in regulating blood pressure. This article provides a detailed list of ACE peptides, exploring their sources, structures, and demonstrated activities, drawing upon extensive scientific literature.

Understanding ACE and its Inhibitors

ACE plays a pivotal role in the renin-angiotensin-aldosterone system (RAAS), which controls fluid and electrolyte balance and blood pressure. It converts angiotensin I to angiotensin II, a potent vasoconstrictor. By inhibiting ACE, these peptides can lower blood pressure. While synthetic ACE inhibitors like captopril, lisinopril, and enalapril are widely used, there's a growing interest in peptides derived from natural sources due to their potential for fewer side effects and additional health benefits, such as antioxidant properties.

Identified ACE Inhibitory Peptides

Research has identified numerous ACE-inhibitory peptides from various sources, including plants, animals, and microorganisms. These peptides vary in length, amino acid sequence, and potency.

From plant sources, studies have highlighted plant-derived ACE-inhibitory peptides. For instance, research has identified Pentapeptide WGPRL and tetrapeptide WLRL from soybean protein, exhibiting non-competitive ACE inhibition and good water solubility. Other identified peptides from plants include those derived from pea protein.

Animal sources have also yielded a rich variety of ACE-inhibitory peptides. For example, soy proteins and products are recognized for their potential to inhibit ACE. Studies have also reported on ACE-inhibitory peptides derived from marine organisms like Takifugu bimaculatus and Ulva intestinalis, with specific examples including ACEIPs isolated from the marine macroalga Ulva intestinalis. Cheedar cheese has been a source for the purification of six novel ACE inhibitory peptides, including VRYL, RYL, YLGY, and TTMP. Porcine liver and placenta have also been explored as sources of novel ACE-inhibitory peptides.

Specific peptide sequences have demonstrated significant ACE inhibitory activity. For example, the RGLSK, NKGPR, DNLLN, and TPCPPQ peptides were identified, with RGLSK showing particularly strong ACE inhibitory effects. Another notable antihypertensive peptide is YKYY, which acts as an ACE inhibitor with a reported IC50 of 64.2 µM. Research has also yielded ACE inhibitory peptides such as FAGDDAPR, QGPIGPR, IFPRNPP, AGFAGDDAPR, and GPTGPAGPR, with IFPRNPP and others showing promising activity. Additionally, FPFPRPP, PPPRGP, PFPRPPH, LGHPW and LKFPDF have been identified as novel ACE inhibitory peptides with IC50 values ranging from 0.271 mg/mL to 1.018 mg/mL.

The literature also presents lists of peptide sequences with potential ACE-inhibitory and antioxidant activities. Some studies focus on specific peptide lengths, such as dipeptides, tripeptides, and tetrapeptides, and those containing five or more residues. For instance, tripeptides with proline at various positions like VPP, IPP, GPP, GPL, LKP, and YPK have shown good ACE inhibition.

Investigating Peptide Properties and Activities

Beyond their ACE inhibitory capacity, many peptides also exhibit other beneficial bioactivities. For instance, several studies have investigated ACE-inhibitory and antioxidant activities of various peptides. The peptide WAFS and the sequence GVQEGAGHYALL have shown enhanced ACE inhibitory activity after pre-incubation. The β-casein derived tripeptide HLP and the dipeptide VM are fragments of known ACE-inhibitor peptides.

The potency of ACE inhibitory peptides is often quantified by their IC50 values, which represent the concentration of the peptide required to inhibit 50% of the enzyme's activity. Peptides with lower IC50 values are considered more potent inhibitors. For example, Tyr-Ser-Met-Tyr-Pro-Pro demonstrated an IC50 of 2.8 µM, while Gly-Tyr had an IC50 of 265 µM. Some studies have identified ACE inhibitory peptides with IC50 values less than 1.0 µM.

Furthermore, the drug-likeness and bioactivity scores of peptides are evaluated to assess their potential as therapeutic agents. Only eight peptides, namely WP, PLW, YPR, LPP, FP, LW, YW, RW, showed positive drug-likeness and bioactivity scores, indicating their potential in pharmaceutical applications.

Future Directions and Potential Applications

The continuous identification and characterization of novel ACE peptides from diverse sources open up exciting avenues for developing functional foods and pharmaceutical interventions for managing hypertension and other cardiovascular